Furthermore, both genetic and pharmacological blockade of IL-17 signaling resulted in increased weight gain, visceral adiposity, and hepatic steatosis; however, these interventions effectively reduced hepatic inflammation and fibrosis in animal models of diet-induced obesity and NAFLD [68, 69], which contradict the above mentioned findings of other authors on the effects of IL-17 on hepatic inflammation and fibrosis [66]. Here, IL17A is linked to obesity disorder.